Emerging data suggest this peptide, a dual agonist targeting both incretin and GIP , appears to represent a promising advancement for obesity management . Initial patient trials have demonstrated impressive reductions in abdominal tissue, conceivably outperforming existing body composition treatments. Nevertheless , further evaluation is required t